Alvogen, Inc.

Alvogen, Inc. is a for-profit pharmaceutical manufacturer headquartered in Morristown, New Jersey, that has been registered in the System for Award Management (SAM.gov) since October 2011. The company specializes in the production of generic pharmaceuticals and medical supplies, serving as an established vendor to the federal government through multiple federal agencies. Alvogen has built a significant business relationship with federal procurement offices, particularly those focused on public health preparedness and military medical supply chain operations, demonstrating consistent capability in fulfilling critical government medical requirements.

Alvogen's federal contract portfolio reveals a comprehensive manufacturing and supply capability across multiple pharmaceutical categories and medical products. The company has received numerous delivery orders from the Defense Logistics Agency (DLA) Troop Support Medical division and the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), with no set-aside designations applied to any of these awards. The company's most significant contract is a $227,679,090.00 delivery order awarded by ASPR in June 2025 for oseltamivir phosphate capsules (Tamiflu) in 75mg and 30mg formulations, destined for the Strategic National Stockpile and scheduled for completion in June 2027. Beyond this major antiviral contract, Alvogen has supplied oxycodone hydrochloride 5mg tablets to DLA Troop Support Medical through numerous smaller delivery orders dating from 2021 through 2023, with individual order values ranging from $16 to approximately $50,700. Additionally, the company has provided clindamycin 150mg/ml injection solutions, labetalol 5mg/ml intravenous solutions, and nitrofurantoin mono-mcr 100mg tablets across various delivery orders. A $461,089.80 purchase order was awarded by the HHS Office of the Assistant Secretary for Administration in July 2021 for general DHHS supplies, further demonstrating the breadth of pharmaceutical products the company provides. All of Alvogen's federal contracts have been awarded on a firm fixed-price basis with no competitive set-asides, indicating the company's established position as a qualified supplier within federal procurement channels.